<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9437">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05697809</url>
  </required_header>
  <id_info>
    <org_study_id>OXUCT-102 - OXEYE</org_study_id>
    <nct_id>NCT05697809</nct_id>
  </id_info>
  <brief_title>Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema</brief_title>
  <acronym>OXEYE</acronym>
  <official_title>A Multi-Center, Randomized, Parallel-Group, Phase 2, Masked, Three-Arm Trial to Compare Safety, Tolerability, Efficacy, and Durability of Two Dose Levels of Suprachoroidal Sustained-Release OXU-001 (Dexamethasone Microspheres; DEXAspheres®) Using the Oxulumis® Illuminated Microcatheterization Device Compared With Intravitreal Dexamethasone Implant (OZURDEX®) in Subjects With Diabetic Macular Edema (OXEYE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxular Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxular Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to compare safety, tolerability, efficacy, and&#xD;
      durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone&#xD;
      microspheres; DEXAspheres®) using the Oxulumis® illuminated microcatheterization device&#xD;
      compared with intravitreal dexamethasone implant (OZURDEX®) in subjects with diabetic macular&#xD;
      edema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty-two (52) week phase 2 trial with two parts. Part A is an open-label, randomized,&#xD;
      single-dose two treatment arm comparison of two dose levels of sustained-release&#xD;
      suprachoroidal OXU-001 (DEXAspheres® administered using the Oxulumis® illuminated&#xD;
      microcatheterization device) in subjects with Diabetic Macular Edema.&#xD;
&#xD;
      Part B is a randomized, masked, active comparator, single-dose, three treatment arm&#xD;
      comparison of two dose levels of suprachoroidal OXU-001 and IVT Ozurdex® to evaluate the&#xD;
      safety, tolerability, efficacy, and durability in subjects with Diabetic Macular Edema (DME).&#xD;
&#xD;
      In Part A, after a screening period, approximately 18 adult female or male subjects will be&#xD;
      randomized in a 1:1 ratio to receive a single administration of one of two dose levels of&#xD;
      OXU-001 (mid-dose or high-dose).&#xD;
&#xD;
      In Part B, after a screening period, approximately 110 adult female or male subjects will be&#xD;
      randomized in a 2:2:1 ratio to receive a single administration of one of two dose levels of&#xD;
      OXU-001 (Dose 1 or Dose 2) or Ozurdex®.&#xD;
&#xD;
      From Week 12, subjects will be assessed for the need for follow-on treatment. The follow-up&#xD;
      period after treatment administration will be up to fifty-two (52) weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2023</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The trial will include previously IVT anti-VEGF treated (in Part A and B) and treatment-naive (in Part B only) DME subjects.&#xD;
In Part A, approximately 18 subjects will be randomly assigned (ratio 1:1) to receive either a mid-dose or high-dose of suprachoroidal OXU-001.&#xD;
In Part B, approximately 110 subjects will be randomly assigned (ratio 2:2:1) to receive a single treatment of either suprachoroidal OXU-001 Dose 1, or Dose 2 or intravitreal Ozurdex®</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part A is open-label, no masking. Part B is masked for the subject and the outcomes assessing site team and central reading center.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of ocular and systemic treatment emergent adverse events, serious adverse events, and adverse events of special interest</measure>
    <time_frame>Week 24</time_frame>
    <description>Treatment-emergent adverse events are defined as events emerging following administration of study treatment at Visit 2 (Baseline, Day 0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent device adverse effects</measure>
    <time_frame>Week 24</time_frame>
    <description>Treatment-emergent device adverse effects are defined as effecs emerging following administration of study treatment at Visit 2 (Baseline, Day 0)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Frequency and severity of ocular and systemic treatment emergent adverse events, serious adverse events, and adverse events of special interest</measure>
    <time_frame>Week 52</time_frame>
    <description>Treatment-emergent adverse events are defined as events emerging following administration of study treatment at Visit 2 (Baseline, Day 0)</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency and severity of treatment-emergent device adverse effects</measure>
    <time_frame>Week 52</time_frame>
    <description>Treatment-emergent device adverse effects are defined as effecs emerging following administration of study treatment at Visit 2 (Baseline, Day 0)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Best-Corrected Visual Acuity (BCVA) compared to baseline, Visit 2, Day 0</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessed using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Central Subfield Thickness (CST) compared to baseline, Visit 2, Day 0</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessed using Spectral-Domain Optical Coherence Tomography (SD-OCT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time interval to subjects requiring follow-on treatment (from baseline, Visit 2, Day 0)</measure>
    <time_frame>From Week 12 through Week 52</time_frame>
    <description>Timepoint for meeting pre-specified criteria of disease activity recurrence</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>A1: OXU-001 / Mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 1 (mid dose) will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2: OXU-001 / High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 2 (high dose) will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1: OXU-001 / Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 1 (mid dose) will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2: OXU-001 / High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 2 (high dose) will be applied. This dose may be adpated based on the outcome of a Week 6 data review of Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B3: Ozurdex®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single treatment with intravitreal Ozurdex®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXU-001</intervention_name>
    <description>Suprachoroidal sustained release dexamethasone acetate</description>
    <arm_group_label>A1: OXU-001 / Mid dose</arm_group_label>
    <arm_group_label>A2: OXU-001 / High Dose</arm_group_label>
    <arm_group_label>B1: OXU-001 / Mid Dose</arm_group_label>
    <arm_group_label>B2: OXU-001 / High Dose</arm_group_label>
    <other_name>DEXAspheres®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Semi-automated suprachoroidal illuminated microcatheter</intervention_name>
    <description>Ophthalmic administration device</description>
    <arm_group_label>A1: OXU-001 / Mid dose</arm_group_label>
    <arm_group_label>A2: OXU-001 / High Dose</arm_group_label>
    <arm_group_label>B1: OXU-001 / Mid Dose</arm_group_label>
    <arm_group_label>B2: OXU-001 / High Dose</arm_group_label>
    <other_name>Oxulumis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex® Ophthalmic Intravitreal Implant</intervention_name>
    <description>Ophthalmic dexamethasone intravitreal implant</description>
    <arm_group_label>B3: Ozurdex®</arm_group_label>
    <other_name>intravitreal dexamethasone implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 or Type 2 diabetes mellitus&#xD;
&#xD;
          -  Diabetic Macular edema involving the center of the fovea in the study eye&#xD;
&#xD;
          -  Best corrected visual acuity in the study eye between 34 and 78 (early treatment of&#xD;
             diabetic retinopathy study) ETDRS letters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macular edema is considered due to a cause other than diabetes mellitus in the study&#xD;
             eye&#xD;
&#xD;
          -  Condition, in the study eye, in which visual acuity is not expected to improve from&#xD;
             the resolution of macular edema&#xD;
&#xD;
          -  Macular laser photocoagulation or panretinal laser photocoagulation in the study eye&#xD;
             performed within 16 weeks prior to screening&#xD;
&#xD;
          -  Active proliferative diabetic retinopathy (PDR) or sequelae of PDR in the study eye&#xD;
&#xD;
          -  Prior treatment with anti-VEGF in the study eye:&#xD;
&#xD;
               1. Treatment naïve group (Part B), any IVT anti-VEGF treatments in the study eye are&#xD;
                  exclusionary regardless of the time interval since injection.&#xD;
&#xD;
               2. Previously treated group (Part A and B), subjects in the previously treated group&#xD;
                  are excluded if they meet any of the below criteria for the study eye at&#xD;
                  screening:&#xD;
&#xD;
                    1. Subject has received less than 3 anti-VEGF injections since treatment&#xD;
                       initiation (at least three injections must have been received for&#xD;
                       eligibility).&#xD;
&#xD;
                    2. Time interval between the first anti-VEGF injection and screening is more&#xD;
                       than 40 weeks.&#xD;
&#xD;
                    3. Last injection with ranibizumab or bevacizumab within 4 weeks prior to&#xD;
                       screening.&#xD;
&#xD;
                    4. Last injection with aflibercept within 8 weeks prior to screening.&#xD;
&#xD;
                    5. Last injection with faricimab or brolucizumab within 12 weeks prior to&#xD;
                       screening.&#xD;
&#xD;
                    6. Prior treatment with SUSVIMO (Port Delivery System) implant is exclusionary.&#xD;
&#xD;
          -  Prior ocular treatment with steroid injections (periocular, subtenon, intravitreal) or&#xD;
             intravitreal implants in the study eye.&#xD;
&#xD;
          -  Prior treatment with suprachoroidal steroids in the study eye is exclusionary.&#xD;
&#xD;
          -  Active malignancy or history of malignancy within the past 5 years&#xD;
&#xD;
          -  Uncontrolled diabetes with a hemoglobin A1c (HbA1c) more than 12% or any other&#xD;
             uncontrolled systemic disease at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Friedrich Asmus, MD</last_name>
    <phone>+44 (0)1865 636200</phone>
    <email>clinicaltrials@oxular.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Sea</last_name>
    <phone>+1 (484) 502-9814</phone>
    <email>clinicaltrials@oxular.com</email>
  </overall_contact_backup>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 13, 2023</study_first_submitted>
  <study_first_submitted_qc>January 24, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 24, 2023</last_update_submitted>
  <last_update_submitted_qc>January 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>Edema</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Retinal Degeneration</keyword>
  <keyword>Retinal Diseases</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormones, Hormone Substitutes, and Hormone Antagonists</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Suprachoroidal Microcatheterization</keyword>
  <keyword>Illuminated Microcatheterization</keyword>
  <keyword>Sustained-Release</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

